Capping Modification Inhibitor Development Service

Capping Modification Inhibitor Development Service at CD BioGlyco

Two types of glycosylation are commonly considered "end-capping" modifications: fucosylation and sialylation. They are found in O-glycans, N-glycans, and glycolipids and are not further modified with other types of glycans. Based on their capping function as well as their unique structures, CD BioGlyco provides capping modification inhibitor development services.

We use a library of glycans as a starting point for high throughput screening for capping modification inhibitors. We screen the library for compounds with capping modification inhibitory effects. Examples include molecules that interfere with the fucosylation of glycans, which can interfere with the function of glycosyltransferases and thus have the effect of inhibiting fucosylation.

On the other hand, we offer the use of luciferase assay, RNA sequencing, and other techniques to test the potency of inhibitors. Cellular models are utilized to assess the selectivity of inhibitors.

Fig.1 Development content of capping modification inhibitor. (CD BioGlyco)

Fucosylation Inhibitor Development Service

Fucosylation is a late step in the glycan biosynthesis pathway catalyzed by fucosyltransferases (FUT). Fucosylation is associated with the development and metastasis of cancer or tumor cells. We provide fucosylation inhibitor development services including, but not limited to, α-1,2-fucosyltransferase inhibitor development, α-1,3-fucosyltransferase inhibitor development, and α-1,6-fucosyltransferase inhibitor development.

Sialylation Inhibitor Development Service

Glycoproteins are capable of being sialylated at different locations, resulting in altered signaling behavior that affects the many pathways in which sialic acid is a key player. At CD BioGlyco, we will provide a variety of sialylation inhibitor development services depending on the receptor target and the types of inhibitor.

Desialylation Inhibitor Development Service

The desialylation reaction regulates a variety of important biological processes in vivo. The catalytic reaction has also been recognized as a potential target for the treatment of a variety of human diseases. At CD BioGlyco, we will provide a desialylation inhibitor development service through the desialylation reaction course.

Applications

Capping modification inhibitors can be used in the study of a wide range of physiological activities. Examples include immune system regulation, cancer progression, angiogenesis, leukocyte adhesion, and host-microbiome interactions.
Capping modification is mostly fucosylation and sialylation, and the development of capping modification inhibitors can be used to probe fucosylation and desialylation on the cell surface.
In medicine, capping modification inhibitors can be used in anti-cancer or anti-tumor studies.

Highlights

We provide our clients with several types of capping modification inhibitor development services, while the development process of each inhibitor includes several branches.
Capping modification is associated with certain physiological activities, and our capping modification inhibitor development services are expected to advance biological research.
We have high-quality capping modification technology to help clients solve capping modification inhibitor R&D problems.

CD BioGlyco relies on professional researchers to provide our clients with high-quality Glycosylation Inhibitor Development Services. We provide our clients with different types of inhibitors according to different types of glycosylation reactions during the development of inhibitors. We have undergone quality testing at every step to ensure our clients' satisfaction. Please feel free to contact us for more detailed information.

Reference

Almahayni, K.; et al. Small molecule inhibitors of mammalian glycosylation. Matrix Biology Plus. 2022, 16: 100108.

This service is for Research Use Only, not intended for any clinical use.